Demand for booster vaccinations against COVID-19 is low in Germany, the association of general practitioners said on Thursday, with some patients waiting for a booster designed to combat the currently circulating Omicron BA.4/5 subvariants.
Tag Archive for: BioNTech
People in Europe should take whatever COVID-19 booster is available to them in the coming months, Emer Cooke, Executive Director of the European Medicines Agency (EMA), said in a Reuters Next Newsmaker interview, ahead of an expected autumn rise in infections.
Israel will offer the updated COVID-19 booster shots from Pfizer/BioNTech designed to combat the Omicron BA.4/5 subvariants by the end of September, a senior health official said on Wednesday.
AstraZeneca Plc on Monday won the dismissal of a U.S. shareholder lawsuit claiming that it concealed problems in developing its COVID-19 vaccine, making it unlikely the treatment would win regulatory approval in the United States.
The European Medicines Agency (EMA) on Monday recommended a COVID-19 booster designed to combat Omicron offshoots BA.4/5, days after endorsing a pair of boosters tailored to target the older BA.1 variant.
The United States is likely to start recommending COVID-19 vaccines annually, health officials said on Tuesday, as new boosters designed to fight currently circulating variants of the coronavirus roll out.
New COVID-19 boosters aimed at fighting currently circulating variants of the coronavirus will be widely available this week, U.S. health officials said on Tuesday, adding that the vaccine is moving closer to an annual jab, as with flu shots.
Pfizer and its German partner BioNTech have filed proceedings at the High Court of England and Wales, seeking a judgment that their COVID-19 vaccine, based on mRNA technology, does not infringe on CureVac’s European patents, according to a regulatory filing on Friday.
Today, the agency amended the EUAs of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine to authorize bivalent formulations of the vaccines for use as a single booster dose at least two months following primary or booster vaccination.
Pending authorization, the Omicron BA.4/BA.5-adapted bivalent vaccine will be available to ship immediately. A conditional marketing authorization application has also been initiated with the European Medicines Agency (EMA) for the Omicron BA.4/BA.5-adapted bivalent vaccine and is expected to be completed in the coming days.
